Country of origin: Cyprus
Pharm-Group: Second generation cephalosporins
Manufacturers: Medokemi Ltd (Cyprus)
International name: Cefuroxime
Synonyms: Zinacef, Zinnat, Ketocef, Kefstar, Kefurox, Multisef, Novocef, Proxim, Supero, Ucefaxim, Cefogen, Cefuxime, Cefurabol, Cefuroxime sodium
Dosage forms: powder for injection solution
Ingredients: Active ingredient - Cefuroxime.
Indications for use: Infections of the upper and lower respiratory tract (acute and chronic bronchitis, infected bronchiectasis, pneumonia, lung abscess, pleural empyema), ear, throat and nose (otitis media, pharyngitis, tonsillitis, sinusitis), skin and soft tissues (erysipelas, cellulitis, pyoderma, impetigo, furunculosis), genitourinary tract (urethritis, acute and chronic pyelonephritis, cystitis, asymptomatic bacteriuria), joints, pelvic and abdominal organs, biliary tract and gastrointestinal tract, wounds, gonorrhea (acute gonococcal urethritis and cervicitis), sepsis, bacterial septicemia, osteomyelitis, peritonitis, meningitis; prevention of infectious complications during operations.
Contraindications: Hypersensitivity (including to other cephalosporins, penicillins, carbapenems), bleeding and gastrointestinal diseases in the anamnesis, incl. nonspecific ulcerative colitis; pregnancy, breastfeeding.
Side effects: Diarrhea, nausea, vomiting, constipation, flatulence, abdominal cramps and pain, dyspepsia, oral ulcers, anorexia, thirst, oral candidiasis, glossitis, pseudomembranous colitis, transient increases in the activity of transaminases, alkaline phosphatase, LDH or bilirubin , liver dysfunction, cholestasis, renal dysfunction, increased creatinine and/or urea nitrogen in the blood serum, decreased creatinine Cl, dysuria, perineal itching, vaginitis, chest pain, shortness of breath, decreased hemoglobin and hematocrit, transient eosinophilia, neutropenia, leukopenia, aplastic and hemolytic anemia, thrombocytopenia, agranulocytosis, hypoprothrombinemia, prolongation of prothrombin time, headache, drowsiness, dysbacteriosis, superinfection, candidiasis, hearing impairment, convulsions (with renal failure), allergic reactions: rash, itching, urticaria; rarely - drug fever or chills, serum sickness, bronchospasm, positive Coombs test, erythema multiforme, interstitial nephritis, Stevens-Johnson syndrome and anaphylactic shock; local reactions: pain or infiltration at the injection site, thrombophlebitis after intravenous administration.
Interaction: Diuretics and nephrotoxic antibiotics increase the risk of kidney damage, NSAIDs - bleeding. Probenecid reduces tubular secretion, reduces renal Cl, increases Cmax, T1/2 and toxicity. Drugs that reduce stomach acidity may reduce the bioavailability of tablets.
Overdose: Symptoms: central nervous system stimulation, convulsions. Treatment: hemodialysis and peritoneal dialysis.
Special instructions: With long-term use, it is recommended to monitor kidney function (especially when using high doses) and prevent dysbacteriosis. In patients with impaired renal function, the dose is reduced (the severity of renal failure and the sensitivity of the pathogen are taken into account). Before intramuscular administration, an aspiration test is performed. After the disappearance of clinical signs of the disease, it should be prescribed for another 2-3 days. A false positive reaction to sugar in the urine may occur. Cefuroxime suspension is active for 10 days.
Literature: Encyclopedia of Medicines 2003